TY - JOUR
T1 - Real-World Effectiveness of Reslizumab in Patients with Severe Eosinophilic Asthma - "First Initiators" and "Switchers"
AU - Hashimoto, Simone
AU - Kroes, Johannes A
AU - Eger, Katrien
AU - Mau-Asam, Pearl
AU - Hofstee, Hendrik B
AU - Bendien, Sarah A
AU - Braunstahl, Gert-Jan
AU - Broeders, Marielle Eac
AU - Imming, Leonie M
AU - Langeveld, Bas
AU - Maitland-van der Zee, Anke H
AU - Oud, Karen Tm
AU - Patberg, Kornelis Wiebe
AU - Smeenk, Frank Wjm
AU - Petronella Romme, Elisabeth Anna
AU - van Bezouw, Maarten J
AU - van de Ven, Marjo Jt
AU - van Veen, Anneke
AU - van Velzen, Edwin
AU - van Veen, Ilonka Hpaa
AU - Weersink, Els Jm
AU - Ten Brinke, Anneke
AU - Sont, Jacob K
AU - Bel, Elisabeth H
AU - RAPSODI team
N1 - Copyright © 2022. Published by Elsevier Inc.
PY - 2022/8
Y1 - 2022/8
N2 - BACKGROUND: Reslizumab, a biologic targeting interleukin-5 has been shown to reduce asthma exacerbations and maintenance oral corticosteroid (OCS) use in randomized controlled trials and pre-post studies in patients with severe eosinophilic asthma. However, real-world effectiveness data of reslizumab are scarce, and it is unknown whether reslizumab has added value after switching from another type-2 biologic.OBJECTIVE: To evaluate (1) real-world effectiveness of reslizumab on severe asthma exacerbations, maintenance OCS-use and overall treatment response, both in biologic naïve patients who initiated reslizumab, and in patients who switched from another type-2 biologic. (2) physicians experience with reslizumab treatment.METHODS: This observational real-world study evaluated data from 134 adults with severe eosinophilic asthma included in the Dutch severe asthma registry (RAPSODI) who initiated reslizumab treatment (4-weekly infusions, 0.3 mg/kg) before April 2020 and had follow-up data ≥6 months. Clinical asthma experts completed surveys on their experience with reslizumab treatment.RESULTS: Overall, reslizumab reduced exacerbation rate (OR(95%CI): 0.10(0.05-0.21), p<0.001), oral corticosteroid use (OR(95%CI) 0.2(0.0-0.5), p<0.001) and maintenance dose, median(CI): 5.0(0.0-10.0) to 0.0(0.0-5.0), p<0.001), with comparable results in biologic-naïve reslizumab initiators and switchers. The overall response to reslizumab was graded 'good' or 'excellent' in 59.2% of patients. The additive effectiveness of reslizumab after switching from another biologic was reflected in physicians' surveys.CONCLUSION: Real-world data show that reslizumab reduces severe asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma, both in biologic-naïve reslizumab initiators and in those who switched from another type-2 biologic. This additional value of reslizumab was recognized by clinical asthma experts.
AB - BACKGROUND: Reslizumab, a biologic targeting interleukin-5 has been shown to reduce asthma exacerbations and maintenance oral corticosteroid (OCS) use in randomized controlled trials and pre-post studies in patients with severe eosinophilic asthma. However, real-world effectiveness data of reslizumab are scarce, and it is unknown whether reslizumab has added value after switching from another type-2 biologic.OBJECTIVE: To evaluate (1) real-world effectiveness of reslizumab on severe asthma exacerbations, maintenance OCS-use and overall treatment response, both in biologic naïve patients who initiated reslizumab, and in patients who switched from another type-2 biologic. (2) physicians experience with reslizumab treatment.METHODS: This observational real-world study evaluated data from 134 adults with severe eosinophilic asthma included in the Dutch severe asthma registry (RAPSODI) who initiated reslizumab treatment (4-weekly infusions, 0.3 mg/kg) before April 2020 and had follow-up data ≥6 months. Clinical asthma experts completed surveys on their experience with reslizumab treatment.RESULTS: Overall, reslizumab reduced exacerbation rate (OR(95%CI): 0.10(0.05-0.21), p<0.001), oral corticosteroid use (OR(95%CI) 0.2(0.0-0.5), p<0.001) and maintenance dose, median(CI): 5.0(0.0-10.0) to 0.0(0.0-5.0), p<0.001), with comparable results in biologic-naïve reslizumab initiators and switchers. The overall response to reslizumab was graded 'good' or 'excellent' in 59.2% of patients. The additive effectiveness of reslizumab after switching from another biologic was reflected in physicians' surveys.CONCLUSION: Real-world data show that reslizumab reduces severe asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma, both in biologic-naïve reslizumab initiators and in those who switched from another type-2 biologic. This additional value of reslizumab was recognized by clinical asthma experts.
U2 - 10.1016/j.jaip.2022.04.014
DO - 10.1016/j.jaip.2022.04.014
M3 - Article
C2 - 35487369
SN - 2213-2198
VL - 10
SP - 2099-2108.e6
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 8
ER -